Ambrx Biopharma (Ambrx Biopharma) EBIT per Share : $-1.63 (TTM As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Ambrx Biopharma EBIT per Share?

Ambrx Biopharma's EBIT per Share for the three months ended in Jun. 2023 was $-0.70. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 was $-1.63.

During the past 3 years, the average EBIT per Share Growth Rate was 15.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Ambrx Biopharma's EBIT per Share or its related term are showing as below:

AMAM' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 15.7 Med: 15.7 Max: 15.7
Current: 15.7

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Ambrx Biopharma was 15.70% per year. The lowest was 15.70% per year. And the median was 15.70% per year.

AMAM's 3-Year EBIT Growth Rate is not ranked
in the Biotechnology industry.
Industry Median: 3.6 vs AMAM: 15.70

Ambrx Biopharma's EBIT for the three months ended in Jun. 2023 was $-35.20 Mil.

Ambrx Biopharma EBIT per Share Historical Data

The historical data trend for Ambrx Biopharma's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ambrx Biopharma EBIT per Share Chart

Ambrx Biopharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

EBIT per Share

-0.60

-0.35

-3.34

-1.95

Ambrx Biopharma Quarterly Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
EBIT per Share	Get a 7-Day Free Trial			-11.52	-1.01	-1.02	-0.93	-0.70

Ambrx Biopharma EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Ambrx Biopharma's EBIT per Share for the fiscal year that ended in Dec. 2022 is calculated as

	EBIT per Share		(A: Dec. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-75.091	/	38.606
=	-1.95

Ambrx Biopharma's EBIT per Share for the quarter that ended in Jun. 2023 is calculated as

	EBIT per Share		(Q: Jun. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-35.202	/	50.477
=	-0.70

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.63

Ambrx Biopharma (NAS:AMAM) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Ambrx Biopharma EBIT per Share Related Terms

Thank you for viewing the detailed overview of Ambrx Biopharma's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Ambrx Biopharma (Ambrx Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ambrx Biopharma Inc (NAS:AMAM) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

AMAM:USA

Address

10975 North Torrey Pines Road, La Jolla, CA, USA, 92037

Website

https://www.ambrx.com

Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.

Executives

Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Margaret Dalesandro	director	ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Sonja Nelson	officer: Chief Financial Officer	C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Daniel J. O'connor	director, officer: President and CEO	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Abhishek Trehan	10 percent owner	WHITELEY CHAMBERS, DON STREET, ST. HELIER Y9 JE2 4TR
Darwin Global Master Fund, Ltd.	10 percent owner	C/O OGIER GLOBAL (CAYMAN) LIMITED, 89 NEXUS WAY, CAMANA BAY, GRAND CAYMAN E9 KY1-9009
Paul V Maier	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Janet Loesberg	director	C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kate Hermans	director	C/O AMBRX BIOPHARMA INC., 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Xiaowei Chang	director	10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Stephen C. Glover	director	108 DOCKSIDE CIRCLE, WESTON FL 33327
Andrew Aromando	officer: Chief Operating Officer	C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Cormorant Private Healthcare Fund Iii Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen	10 percent owner	C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116